title: Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes.
abstract: BACKGROUND
  To evaluate the effect of the sustained-release formulation of indapamide (indapamide SR) in type 2 diabetic patients with mild-to-moderate hypertension and its possible side effects, particularly on glucose metabolism and lipid profiles.
  
  
  METHODS
  A total of 64 patients randomly received 1.5 mg of indapamide SR or placebo once daily for 3 months. The effects were evaluated by 24-h ambulatory blood pressure monitor, fasting blood sampling for biochemistry, lipid profiles, and frequently sampled intravenous glucose tolerance test.
  
  
  RESULTS
  The changes in standing and supine blood pressure (BP) were significant (154.7 +/- 9.4/94 +/- 2.9 mm Hg v 134.4 +/- 5.1/82.4 +/- 5 mm Hg and 155 +/- 9.8/94.6 +/- 3.6 mm Hg v 135.1 +/- 4.9/82.1 +/- 4.7 mm Hg) in the indapamide group, but not in the placebo group. According to the 24-h ambulatory blood pressure monitor reading, a significant reduction was observed in not only in the whole-day mean BP (mean systolic BP/mean diastolic BP, 149 +/- 19.3/87.6 +/- 11.3 mm Hg v 135.7 +/- 12.6/79.6 +/- 9 mm Hg) but also the whole-day mean median arterial pressure (109 +/- 12.7 mm Hg v 98.7 +/- 8.2 mm Hg) for the indapamide group, but not the placebo group. There were no changes in biochemical data including serum sodium, potassium, chloride, uric acid, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine, lipid profiles, fasting blood glucose, insulin, hemoglobin Alc, and glucose metabolism parameters (insulin sensitivity, glucose effectiveness, and acute insulin response) from frequently sampled intravenous glucose tolerance test after indapamide or placebo therapy.
  
  
  CONCLUSIONS
  Indapamide SR can significantly lower the whole-day BP in hypertensive patients with type 2 diabetes. Also, it did not alter or aggravate patients' lipid profiles, glucose metabolism, and did not exert possible side effects of hypokalemia and hyperuricemia. Therefore, monotherapy with indapamide SR should be suggested in type 2 diabetic patients with mild-to-moderate hypertension.
authors.affiliation: Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325 Cheng-kung Road, Section 2, Neihu 114, Taipei, Taiwan, R.O.C. perryguo@seed.net.tw
authors.forename: Shi-Wen
authors.initials: SW
authors.lastname: Kuo
authors.lastname: Pei-Dee
authors.forename: Yi-Jen
authors.initials: YJ
authors.lastname: Hung
authors.forename: An-Tsz
authors.initials: AT
authors.lastname: Hsieh
authors.forename: Ling-Yi
authors.initials: LY
authors.lastname: Wu
authors.forename: Chang-Hsun
authors.initials: CH
authors.lastname: Hsieh
authors.forename: Chih-Tsueng
authors.initials: CT
authors.lastname: He
authors.forename: Tsao-Chin
authors.initials: TC
authors.lastname: Yang
authors.forename: Wei-Cheng
authors.initials: WC
authors.lastname: Lian
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D007190:Indapamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011187:Posture / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose; D003692:Delayed-Action Preparations; D007328:Insulin; D008055:Lipids; D007190:Indapamide